Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 676053, 12 pages
http://dx.doi.org/10.1155/2015/676053
Review Article

Well-Designed Bone-Seeking Radiolabeled Compounds for Diagnosis and Therapy of Bone Metastases

Division of Pharmaceutical Sciences, Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan

Received 24 July 2014; Revised 4 October 2014; Accepted 8 October 2014

Academic Editor: Bishnuhari Paudyal

Copyright © 2015 Kazuma Ogawa and Atsushi Ishizaki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Subramanian, J. G. McAfee, R. J. Blair, F. A. Kallfelz, and F. D. Thomas, “Technetium 99m methylene diphosphonate: a superior agent for skeletal imaging: comparison with other technetium complexes,” Journal of Nuclear Medicine, vol. 16, no. 8, pp. 744–755, 1975. View at Google Scholar · View at Scopus
  2. P. A. Domstad, J. J. Coupal, and E. E. Kim, “99mTc-hydroxymethane diphosphonate: a new bone imaging agent with a low tin content,” Radiology, vol. 136, no. 1, pp. 209–211, 1980. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Love, A. S. Din, M. B. Tomas, T. P. Kalapparambath, and C. J. Palestro, “Radionuclide bone imaging: an illustrative review,” Radiographics, vol. 23, no. 2, pp. 341–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Mari, A. Catafau, and I. Carrio, “Bone scintigraphy and metabolic disorders,” Quarterly Journal of Nuclear Medicine, vol. 43, no. 3, pp. 259–267, 1999. View at Google Scholar · View at Scopus
  5. J. Davis, N. D. Cook, and R. J. Pither, “Biologic mechanisms of 89SrCl2 incorporation into type I collagen during bone mineralization,” Journal of Nuclear Medicine, vol. 41, no. 1, pp. 183–188, 2000. View at Google Scholar · View at Scopus
  6. F. M. Paes and A. N. Serafini, “Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain,” Seminars in Nuclear Medicine, vol. 40, no. 2, pp. 89–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. F. M. Paes, V. Ernani, P. Hosein, and A. N. Serafini, “Radiopharmaceuticals: when and how to use them to treat metastatic bone pain,” Journal of Supportive Oncology, vol. 9, no. 6, pp. 197–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Liepe and J. Kotzerke, “Internal radiotherapy of painful bone metastases,” Methods, vol. 55, no. 3, pp. 258–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Ogawa and K. Washiyama, “Bone target radiotracers for palliative therapy of bone metastases,” Current Medicinal Chemistry, vol. 19, no. 20, pp. 3290–3300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. F. Eary, C. Collins, M. Stabin et al., “Samarium-153-EDTMP biodistribution and dosimetry estimation,” Journal of Nuclear Medicine, vol. 34, no. 7, pp. 1031–1036, 1993. View at Google Scholar · View at Scopus
  11. L. Bianchi, A. Baroli, L. Marzoli, C. Verusio, C. Chiesa, and L. Pozzi, “Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 1, pp. 122–129, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. J. Dickie and D. Macfarlane, “Strontium and samarium therapy for bone metastases from prostate carcinoma,” Australasian Radiology, vol. 43, no. 4, pp. 476–479, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. M. G. E. H. Lam, A. Dahmane, W. H. M. Stevens, P. P. Van Rijk, J. M. H. De Klerk, and B. A. Zonnenberg, “Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 4, pp. 756–765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Parker, S. Nilsson D Heinrich, S. I. Helle et al., “Alpha emitter radium-223 and survival in metastatic prostate cancer,” The New England Journal of Medicine, vol. 369, no. 3, pp. 213–223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Sartor, R. Coleman, S. Nilsson et al., “Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial,” The Lancet Oncology, vol. 15, no. 7, pp. 738–746, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. J. P. Tanabe Zodda, E. Deutsch, and W. R. Heineman, “Effect of pH on the formation of Tc(NaBH4)-MDP radiopharmaceutical analogues,” International Journal of Applied Radiation and Isotopes, vol. 34, no. 12, pp. 1577–1584, 1983. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Libson, E. Deutsch, and B. L. Barnett, “Structural characterization of a 99Tc-diphosphonate complex. Implications for the chemistry of 99mTc skeletal imaging agents,” Journal of the American Chemical Society, vol. 102, no. 7, pp. 2476–2478, 1980. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Verbeke, J. Rozenski, B. Cleynhens et al., “Development of a conjugate of 99mTc-EC with aminomethylenediphosphonate in the search for a bone tracer with fast clearance from soft tissue,” Bioconjugate Chemistry, vol. 13, no. 1, pp. 16–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Ogawa, T. Mukai, Y. Inoue, M. Ono, and H. Saji, “Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent,” Journal of Nuclear Medicine, vol. 47, no. 12, pp. 2042–2047, 2006. View at Google Scholar · View at Scopus
  20. L. Liu, G. Zhong, Y. Wei, M. Zhang, and X. Wang, “Synthesis and biological evaluation of a novel 99mTc complex of HYNIC-conjugated aminomethylenediphosphonate as a potential bone imaging agent,” Journal of Radioanalytical and Nuclear Chemistry, vol. 288, no. 2, pp. 467–473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Liu, D. S. Edwards, R. J. Looby et al., “Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands,” Bioconjugate Chemistry, vol. 7, no. 1, pp. 63–71, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Ono, Y. Arano, T. Uehara et al., “Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins,” Bioconjugate Chemistry, vol. 10, no. 3, pp. 386–394, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Ono, Y. Arano, T. Mukai et al., “Plasma protein binding of 99mTc-labeled hydrazino nicotinamide derivatized polypeptides and peptides,” Nuclear Medicine and Biology, vol. 28, no. 2, pp. 155–164, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Palma, B. L. Oliveira, J. D. G. Correia, L. Gano, L. Maria, and I. C. Santos, “A new bisphosphonate-containing 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation,” Journal of Biological Inorganic Chemistry, vol. 12, no. 5, pp. 667–679, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Palma, J. D. G. Correia, B. L. Oliveira, L. Gano, and I. C. Santos, “99mTc(CO)3-labeled pamidronate and alendronate for bone imaging,” Dalton Transactions, vol. 40, no. 12, pp. 2787–2796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Van Beek, M. Hoekstra, M. van de Ruit, C. Löwik, and S. Papapoulos, “Structural requirements for bisphosphonate actions in vitro,” Journal of Bone and Mineral Research, vol. 9, no. 12, pp. 1875–1882, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Meyer and G. H. Nancollas, “The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite,” Calcified Tissue Research, vol. 13, no. 1, pp. 295–303, 1973. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Ogawa, T. Mukai, Y. Arano et al., “Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation,” Nuclear Medicine and Biology, vol. 33, no. 4, pp. 513–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. T. M. De Rosales, C. Finucane, S. J. Mather, and P. J. Blower, “Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases,” Chemical Communications, no. 32, pp. 4847–4849, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. K. P. Zhernosekov, D. V. Filosofov, R. P. Baum et al., “Processing of generator-produced 68Ga for medical application,” Journal of Nuclear Medicine, vol. 48, no. 10, pp. 1741–1748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Fellner, R. P. Baum, V. Kubíček et al., “PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 4, article 834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Fellner, B. Biesalski, N. Bausbacher et al., “68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter,” Nuclear Medicine and Biology, vol. 39, no. 7, pp. 993–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. Ø. S. Bruland, S. Nilsson, D. R. Fisher, and R. H. Larsen, “High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities?” Clinical Cancer Research, vol. 12, no. 20, part 2, pp. 6250s–6257s, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Ogawa, K. Takai, H. Kanbara et al., “Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent,” Nuclear Medicine and Biology, vol. 38, no. 5, pp. 631–636, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Suzuki, M. Satake, J. Suwada et al., “Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging,” Nuclear Medicine and Biology, vol. 38, no. 7, pp. 1011–1018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Ferro-Flores and C. Arteaga de Murphy, “Pharmacokinetics and dosimetry of 188Re-pharmaceuticals,” Advanced Drug Delivery Reviews, vol. 60, no. 12, pp. 1389–1401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. F. F. Knapp Jr., A. L. Beets, S. Guhlke et al., “Availability of rhenium-188 from the alumina-based tungsten-188/Rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment,” Anticancer Research, vol. 17, no. 3, pp. 1783–1795, 1997. View at Google Scholar · View at Scopus
  38. K. Liepe, R. Runge, and J. Kotzerke, “The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain,” Journal of Cancer Research and Clinical Oncology, vol. 131, no. 1, pp. 60–66, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. I. G. Finlay, M. D. Mason, and M. Shelley, “Radioisotopes for the palliation of metastatic bone cancer: a systematic review,” The Lancet Oncology, vol. 6, no. 6, pp. 392–400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Deutsch, K. Libson, J. L. Vanderheyden, A. R. Ketring, and H. R. Maxon, “The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine,” Nuclear Medicine and Biology, vol. 13, no. 4, pp. 465–477, 1986. View at Google Scholar · View at Scopus
  41. Y. Arano, M. Ono, K. Wakisaka et al., “Synthesis and biodistribution studies of 186Re complex of 1-hydroxyethylidene-1,1-diphosphonate for treatment of painful osseous metastases,” Radioisotopes, vol. 44, no. 8, pp. 514–522, 1995. View at Google Scholar
  42. F. De Winter, B. Brans, C. Van De Wiele, and R. A. Dierckx, “Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma,” Clinical Nuclear Medicine, vol. 24, no. 11, pp. 898–899, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. G. S. Limouris, S. K. Shukla, A. Condi-Paphiti et al., “Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases,” Anticancer Research, vol. 17, no. 3B, pp. 1767–1772, 1997. View at Google Scholar
  44. W.-Y. Lin, J.-F. Hsieh, S.-C. Tsai, T.-C. Yen, S. J. Wang, and F. F. Knapp Jr., “A comprehensive study on the blockage of thyroid and gastric uptakes of 188Re-perrhenate in endovascular irradiation using liquid-filled balloon to prevent restenosis,” Nuclear Medicine and Biology, vol. 27, no. 1, pp. 83–87, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Ogawa, T. Mukai, Y. Arano et al., “Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 47, no. 11, pp. 753–761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Ogawa, T. Mukai, Y. Arano et al., “Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals,” Bioconjugate Chemistry, vol. 16, no. 4, pp. 751–757, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Ogawa, T. Mukai, D. Asano et al., “Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model,” Journal of Nuclear Medicine, vol. 48, no. 1, pp. 122–127, 2007. View at Google Scholar · View at Scopus
  48. T. Uehara, Z. L. Jin, K. Ogawa et al., “Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones,” Nuclear Medicine and Biology, vol. 34, no. 1, pp. 79–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. R. T. M. de Rosales, C. Finucane, J. Foster, S. J. Mather, and P. J. Blower, “188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases,” Bioconjugate Chemistry, vol. 21, no. 5, pp. 811–815, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. W. T. Butler, “The nature and significance of osteopontin,” Connective Tissue Research, vol. 23, no. 2-3, pp. 123–136, 1989. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Oldberg, A. Franzen, and D. Heinegard, “The primary structure of a cell-binding bone sialoprotein,” The Journal of Biological Chemistry, vol. 263, no. 36, pp. 19430–19432, 1988. View at Google Scholar · View at Scopus
  52. A. Oldberg, A. Franzen, and D. Heinegard, “Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 23, pp. 8819–8823, 1986. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kasugai, R. Fujisawa, Y. Waki, K.-I. Miyamoto, and K. Ohya, “Selective drug delivery system to bone: Small peptide (Asp)6 conjugation,” Journal of Bone and Mineral Research, vol. 15, no. 5, pp. 936–943, 2000. View at Google Scholar · View at Scopus
  54. K. Yokogawa, K. Miya, T. Sekido et al., “Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice,” Endocrinology, vol. 142, no. 3, pp. 1228–1233, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Wang, S. Miller, M. Sima, P. Kopečková, and J. Kopeček, “Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems,” Bioconjugate Chemistry, vol. 14, no. 5, pp. 853–859, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Yanagi, T. Uehara, Y. Uchida et al., “Chemical design of 99mTc-labeled probes for targeting osteogenic bone region,” Bioconjugate Chemistry, vol. 24, no. 7, pp. 1248–1255, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Ogawa, A. Ishizaki, K. Takai et al., “Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers,” PLoS ONE, vol. 8, no. 12, Article ID e84335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Novinec and B. Lenarčic, “Cathepsin K: a unique collagenolytic cysteine peptidase,” Biological Chemistry, vol. 394, no. 9, pp. 1163–1179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Troeberg and H. Nagase, “Proteases involved in cartilage matrix degradation in osteoarthritis,” Biochimica et Biophysica Acta: Proteins and Proteomics, vol. 1824, no. 1, pp. 133–145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. K. M. Kozloff, L. Quinti, S. Patntirapong et al., “Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo,” Bone, vol. 44, no. 2, pp. 190–198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. M. E. Rodnick, X. Shao, K. M. Kozloff, P. J. H. Scott, and M. R. Kilbourn, “Carbon-11 labeled cathepsin K inhibitors: syntheses and preliminary in vivo evaluation,” Nuclear Medicine and Biology, vol. 41, no. 5, pp. 384–389, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Altmann, R. Aichholz, C. Betschart et al., “2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K,” Journal of Medicinal Chemistry, vol. 50, no. 4, pp. 591–594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Weissleder and U. Mahmood, “Molecular imaging,” Radiology, vol. 219, no. 2, pp. 316–333, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. V. Ntziachristos, C. Bremer, and R. Weissleder, “Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging,” European Radiology, vol. 13, no. 1, pp. 195–208, 2003. View at Google Scholar · View at Scopus
  65. A. Zaheer, R. E. Lenkinski, A. Mahmood, A. G. Jones, L. C. Cantley, and J. V. Frangioni, “In vivo near-infrared fluorescence imaging of osteoblastic activity,” Nature Biotechnology, vol. 19, no. 12, pp. 1148–1154, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. K. R. Bhushan, P. Misra, F. Liu, S. Mathur, R. E. Lenkinski, and J. V. Frangioni, “Detection of breast cancer microcalcifications using a dual-modality SPECT/ NIR fluorescent probe,” Journal of the American Chemical Society, vol. 130, no. 52, pp. 17648–17649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Pandit-Taskar, S. M. Larson, and J. A. Carrasquillo, “Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: alpha therapy with 223Ra-dichloride,” Journal of Nuclear Medicine, vol. 55, no. 2, pp. 268–274, 2014. View at Publisher · View at Google Scholar